COVID-19 is not yet in the past, but UK medtech market access schemes are starting to resume their pre-pandemic momentum. The Accelerated Access Collaborative (AAC) programs are back up and running and the next round of Rapid Uptake Product (RUP) assessments has kicked off. And the Medtech Funding Mandate has “gone live,” on 1 April – albeit one year behind plan.
In addition, the UK Association of British HealthTech Industries (ABHI) is developing a proposal for a new conditional reimbursement with evidence scheme that would target promising technologies that have not generated enough evidence
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?